Wave Life Sciences’ WVE-007 Achieves 4% Total Fat and 9.2% Visceral Fat Reduction
Wave Life Sciences delivered obesity asset WVE-007 placebo-adjusted reductions of 4% total fat and 9.2% visceral fat with a single 240 mg dose while preserving lean mass. The company ended 2025 with $602.1 M in cash, funding operations into Q3 2028 and outlined multiple 2026 clinical data catalysts.
1. Financial Results and Runway
Wave Life Sciences posted a full-year net loss of $204.4 million for 2025 and ended the year with $602.1 million in cash, which management expects will fund operations into the third quarter of 2028.
2. INLIGHT Phase I Efficacy and Safety
In the INLIGHT trial, a single 240 mg dose of WVE-007 achieved placebo-adjusted reductions of about 4% total fat and 9.2% visceral fat while preserving lean mass with a 0.9% increase, alongside a favorable safety and pharmacokinetic profile and sustained Activin E level reductions.
3. Upcoming WVE-007 Trials and Milestones
Wave plans to initiate a Phase IIa multi-dose portion of INLIGHT in the first half of 2026, enrolling participants with higher BMI and comorbidities to include MRI-PDFF liver-fat assessments, and will launch incretin add-on and post-incretin maintenance trials later in 2026.
4. RNA Editing Programs and Regulatory Path
The RNA editing pipeline is advancing with WVE-006 for AATD targeting mid-2026 feedback on an accelerated-approval pathway after 400 mg multi-dose data due this quarter and 600 mg data in 2026, while WVE-008 for PNPLA3 I148M and the WVE-N531 NDA for DMD remain on track for 2026 milestones.